To express the sense of the House of Representatives regarding the Medicare national coverage determination on the treatment of anemia in cancer patients.

Expresses the sense of the House of Representatives that the Centers for Medicare and Medicaid Services should: (1) begin an immediate reconsideration of the final National Coverage Determination on the Use of Erythropoiesis Stimulating Agents in Cancer and Related Neoplastic Conditions; (2) consult with members of the clinical oncology community to determine appropriate revisions to such Determination; and (3) implement appropriate revisions to such Determination as soon as feasible and provide a briefing to Congress in advance of announcing such changes.